Systematic Financial Management LP Has $5.15 Million Position in Omnicell, Inc. $OMCL

Systematic Financial Management LP trimmed its position in Omnicell, Inc. (NASDAQ:OMCL) by 10.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 113,619 shares of the company’s stock after selling 13,288 shares during the quarter. Systematic Financial Management LP owned 0.25% of Omnicell worth $5,147,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP grew its holdings in Omnicell by 9.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,364,068 shares of the company’s stock valued at $71,985,000 after buying an additional 197,462 shares in the last quarter. Lazard Asset Management LLC grew its holdings in Omnicell by 3.8% in the 2nd quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company’s stock valued at $50,225,000 after buying an additional 62,733 shares in the last quarter. Millennium Management LLC acquired a new position in Omnicell in the 3rd quarter valued at $25,625,000. Wellington Management Group LLP grew its holdings in Omnicell by 0.7% in the 3rd quarter. Wellington Management Group LLP now owns 809,544 shares of the company’s stock valued at $24,651,000 after buying an additional 5,384 shares in the last quarter. Finally, Qube Research & Technologies Ltd grew its holdings in Omnicell by 38.4% in the 2nd quarter. Qube Research & Technologies Ltd now owns 653,971 shares of the company’s stock valued at $19,227,000 after buying an additional 181,394 shares in the last quarter. 97.70% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Omnicell news, EVP Corey J. Manley sold 5,025 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $43.22, for a total value of $217,180.50. Following the completion of the sale, the executive vice president owned 112,783 shares of the company’s stock, valued at approximately $4,874,481.26. This trade represents a 4.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Nnamdi Njoku sold 3,090 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $133,549.80. Following the completion of the transaction, the executive vice president owned 154,785 shares in the company, valued at $6,689,807.70. This represents a 1.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 15,520 shares of company stock valued at $607,610 in the last three months. Insiders own 2.92% of the company’s stock.

Omnicell Stock Performance

NASDAQ OMCL opened at $44.41 on Monday. The business has a 50 day simple moving average of $38.04 and a 200 day simple moving average of $40.83. Omnicell, Inc. has a one year low of $26.84 and a one year high of $55.00. The stock has a market capitalization of $2.02 billion, a P/E ratio of 100.93, a P/E/G ratio of 1.15 and a beta of 0.96. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.50 and a quick ratio of 1.29.

Omnicell (NASDAQ:OMCL) last released its earnings results on Tuesday, April 28th. The company reported $0.55 EPS for the quarter, topping the consensus estimate of $0.33 by $0.22. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The business had revenue of $309.88 million during the quarter, compared to analysts’ expectations of $304.02 million. During the same quarter last year, the firm posted $0.26 earnings per share. The firm’s revenue was up 14.9% on a year-over-year basis. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. Research analysts expect that Omnicell, Inc. will post 1.31 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have commented on the company. UBS Group set a $60.00 price objective on Omnicell and gave the company a “buy” rating in a report on Friday, March 13th. KeyCorp increased their target price on Omnicell from $60.00 to $70.00 and gave the stock an “overweight” rating in a report on Tuesday, April 28th. Wall Street Zen raised Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 10th. Wells Fargo & Company increased their target price on Omnicell from $52.00 to $55.00 and gave the stock an “overweight” rating in a report on Thursday, April 23rd. Finally, Weiss Ratings raised Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a research note on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $59.86.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.